GSK and Medicago to Initiate P-I Trial of Plant-Based COVID-19 Vaccine in July 2020

 GSK and Medicago to Initiate P-I Trial of Plant-Based COVID-19 Vaccine in July 2020

GSK and Medicago to Initiate P-I Trial of their COVID-19 Vaccine in July 2020

Shots:

  • The two companies collaborated to develop a COVID-19 vaccine combining Medicago’s recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK’s pandemic adjuvant system. The partners are planning to initiate P-I study in mid-July followed by pre-clinical results that showed combining the two platforms demonstrated a high level of neutralizing Abs following a single dose
  • The study will evaluate the safety and immunogenicity of three different dose levels of antigen combined with GSK’s adjuvant and compared it with adjuvant of another company, administered on a one- and two-dose vaccination schedule, given 21 days apart
  • Medicago will leverage its plant-based production platform to manufacture the COVID-19 vaccine antigen by using the leaves of a plant as bioreactors to produce the S-spike protein which self-assembles into VLPs for use in the CoVLP vaccine candidate. The companies aim to complete the development and make it available in H1’21 and expect to manufacture ~100M doses by the end of 2021

Click here to read full press release/ article | Ref: GSK | Image: Medicago

Related News: Sanofi and GSK Collaborate to Develop Adjuvanted COVID-19 Vaccine

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post